Drug Database
Back to search

Poland· PL-100204998

Polstigminum

A neostigmine product containing neostigmini metilsulfas, registered in Poland by Teva Pharmaceuticals Polska Sp. z o.o.. The same ATC class is registered in 10 of our 19 countries.

ATC N07AA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPolstigminumATCN07AA01REGISTER NO.PL-100204998PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about neostigmini metilsulfasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Neostigmine is registered in 10 of 19 countries.

Countries holding a registration under ATC N07AA01 (neostigmine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search neostigmine products by name

Neostigmine · ATC N07AA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Neostigmini metilsulfas
Manufacturer
Teva Pharmaceuticals Polska Sp. z o.o.
Country
Poland (PL)
ATC code
N07AA01
ATC class
Neostigmine
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909990115211

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

68 interactions on record for neostigmine.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check neostigmine against other medicinesHow interaction checks work

Neostigmine · interactions on record

68 records

  • 6 severe
  • 62 moderate

Most severe, free to view

  • SiponimodL04AA42severe
  • SiponimodL04AE03severe
  • BupropionN06AX12severe
  • BupropionN07BA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Neostigmine in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All neostigmine products

Authorised across Europe · EMA

The same active substance is authorised in 16 EEA countries. Names it is sold under:

  • Austria · Neostig, Normastigmin
  • Cyprus · Neostigmine Cooper
  • Czechia · Syntostigmin
  • Germany · Neostig, Neostigmin Panpharma
  • Spain · Neostigmina Braun
  • France · Néostigmine Renaudin, Prostigmine
  • United Kingdom (Northern Ireland) · Neostigmine Methylsulfate Bp Hameln Pharma
  • Greece · Neostigmine Cooper
  • Croatia · Neostigmin Panpharma
  • Hungary · Neostigmine Kalceks, Stigmosan
  • Latvia · Neostigmine Kalceks
  • Netherlands · Neostigminemethylsulfaat Cf, Prostigmin
  • Portugal · Neostigmina Braun
  • Romania · Miostin
  • Sweden · Neostigmin Unimedic Pharma Ab
  • Slovakia · Syntostigmin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5c47bb4b-5ae3-4f12-a2a2-e0722ad903e6
GET /v1/drugs/5c47bb4b-5ae3-4f12-a2a2-e0722ad903e6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "0,5 mg/ml",
  "packaging": "05909990115211 ¦ Rp ¦ 53514\n10 amp. 1 ml",
  "substance": "Neostigmini methylsulfas 0.5 mg/ml",
  "common_name": "Neostigmini metilsulfas",
  "pl_product_id": "100204998",
  "pozwolenie_nr": "01152",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about neostigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console